Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypofractionated Radiotherapy with Durvalumab and Tremelimumab in Metastatic Cancers
NCT02639026Phase 1Completed
- Sponsor
- Abramson Cancer Center
- Start
- Jan 2016
- Primary completion
- Jun 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of durvalumab and tremelimumab in melanoma, non-small cell lung cancer (NSCLC), breast cancer and 1 more (2 cohorts), sponsored by Abramson Cancer Center. Primary endpoint: Number of Adverse Events at 12 months. Started Jan 2016; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
melanomanon-small cell lung cancer (NSCLC)breast cancerpancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02639026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02639026.